H2 Inc
TTPEX:785131.10
TWD
-1.50
(-4.60%)
ISIN
KYG4711S1030
CUSIP
G4711S103
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Ed Deng
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Taipei Taiwan
- Website
- health2sync.com
- Similar Companies
- Business
- H2 Inc. is a digital healthcare technology company that develops and operates integrated software and connected solutions for chronic condition management, specializing in diabetes, hypertension, and metabolic health. The company provides a proprietary chronic care ecosystem consisting of the Health2Sync mobile application, a patient-facing digital health tool for automated blood glucose logging, blood pressure tracking, lifestyle monitoring, AI-powered visual meal recognition, and personalized behavioral intervention; the Health2Sync Patient Management Platform, a cloud-based clinical portal that delivers remote patient monitoring, longitudinal health data analytics, and decision-support tools for physicians, nurses, and certified diabetes educators; IoT connectivity hardware and synchronization modules, including the proprietary Health2Sync Smart Cable and wireless integrations connecting standard glucometers, continuous glucose monitoring systems, blood pressure monitors, and smart insulin pen devices; and enterprise InsurTech and digital therapeutics solutions, offering real-world data analytics, chronic disease management programs, and health risk assessment algorithms for pharmaceutical companies, life insurers, and healthcare organizations. The company serves individual patients, hospitals, clinics, medical device manufacturers, multinational pharmaceutical corporations, and health insurance providers across East and Southeast Asia and the Asia-Pacific region, including Taiwan, Japan, South Korea, Singapore, Hong Kong, and Australia. In November 2025, H2 Inc. listed its shares on the Emerging Stock Board of the Taipei Exchange under ticker 7851, implementing a flexible par value system. In March 2025, the company completed a Series C financing round exceeding 20 million U.S. dollars led by Taiwania Capital, with participation from strategic and institutional investors including Pegatron, Wistron, BE Health Ventures, ABIES Capital, and Cathay Venture, bringing total capital raised to more than 30 million U.S. dollars to accelerate international expansion and artificial intelligence research and development. Recent strategic initiatives include commercial partnerships with Novo Nordisk to integrate the Mallya smart insulin cap into the South Korean market, integration partnerships with Abbott to connect FreeStyle Libre continuous glucose monitors with localized platforms such as Sugar Genie, collaboration with the Singapore Health Promotion Board and Abbott to deliver the DigiCoach metabolic and weight management initiative, and clinical deployment partnerships with Western Sydney Diabetes. Founded in 2013, H2 Inc. is incorporated in the Cayman Islands and maintains its principal executive headquarters in Taipei, Taiwan, with international operational subsidiaries and branch offices in Tokyo, Japan, and Seoul, South Korea.